Prostatic adenosis and dysplasia. what is their definition... and their significance? Are there "precancerous" lesions in prostatic pathology?
Vieillefond, A.; Berger, N.; Dauge-Geffroy, M.C.; Saint Andre, J.P.
Annales de Pathologie 13(2): 85-87
1993
ISSN/ISBN: 0242-6498 PMID: 7689844 Document Number: 411588
Document emailed within 1 workday
Related Documents
Bordes, M.; Brunet-Lecomte, P.; Dusserre, P.; Dusserre-Guion, L.; Michiels-Marzais, D.; Morlevat, F.; Peny, J.; Roignot, P.; Colas, J.M.; Ferry, N. 1989: Prostatic specific antigen and prostatic pathology. Value of preoperative blood assay. Preliminary study apropos of 709 case reports Annales d'Urologie 23(4): 295-300Shiran, M.S.; Tan, G.C.; Sabariah, A.R.; Rampal, L.; Phang, K.S. 2007: P63 as a complimentary basal cell specific marker to high molecular weight-cytokeratin in distinguishing prostatic carcinoma from benign prostatic lesions Medical Journal of Malaysia 62(1): 36-39
Bogdanowicz, J.F.; Bentvelsen, F.M.; Oosterom, R.; Schroeder, F.H. 1991: Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia Scandinavian Journal of Urology and Nephrology. Supplementum 138: 97-103
Svanholm, H.; Hørder, M. 1988: Clinical application of prostatic markers. I. Classification of prostatic tumours using immunohistochemical techniques Scandinavian Journal of Urology and Nephrology. Supplementum 107: 65-70
Cecchi, M.; Sepich, C.A.; Pagni, G.L.; Summonti, D.; Ippolito, C.; Di Benedetto, A.; Bertolini, L.; Minervini, R.; Fiorentini, L. 1998: Prostatic endoprosthesis in the treatment of prostatic obstruction: preliminary experience with the new Trestle model Chirurgia Italiana 50(1): 37-40
Brannen, G.E.; Coffey, D.S. 1977: Tumor-specific immunity in patients with prostatic adenocarcinoma or benign prostatic hyperplasia Cancer Treatment Reports 61(2): 211-216
Sáenz de Chirife, A.M.; Bassi, A.M.; Celeste, F.; Bergdolt, D. 1991: Specific prostatic antigen in prostatic carcinoma: its relationship with tumor differentiation and clinical course Archivos Espanoles de Urologia 44(4): 405-409
Bouffioux, C. 1983: Prostatic cytology. Value of the technic in the diagnosis and surveillance of prostatic carcinomas; viewpoint of the urologist Acta Urologica Belgica 51(1): 56-71
Paul, B.D.; Serrano, J.A.; Friedman, A.E.; Sarlos, I.J.; Sternberger, N.J.; Wasserkrug, H.L.; Seligman, A.M. 1977: New agents for prostatic cancer activated specifically by prostatic acid phosphatase Cancer Treatment Reports 61(2): 259-263
Rodríguez Rodríguez, R.; Mayayo Dehesa, T.; Galbis Sanjuan, F.; Burgos Revilla, F.J.; Jiménez Cidre, M.; García González, R. 1996: Chronic prostatic inflammation: a confounding factor in the diagnosis of prostatic cancer Archivos Espanoles de Urologia 49(7): 669-673
Kletscher, B.A.; Oesterling, J.E. 1995: Prostatic stents. Current perspectives for the management of benign prostatic hyperplasia Urologic Clinics of North America 22(2): 423-430
Gu, F. 2000: Epidemiological survey of benign prostatic hyperplasia and prostatic cancer in China Chinese Medical Journal 113(4): 299-302
Strohmenger, P. 1980: Prostatic adenoma--prostatic carcinoma. Questions from general practice. II. Therapy Zfa. Zeitschrift für Allgemeinmedizin 56(28): 1793-1797
Blanc, M.; Sacrini, A.; Avogadro, A.; Gattamorta, M.; Lazzerini, F.; Gattoni, F.; Cretti, F. 1998: Prostatic volume: suprapubic versus transrectal ultrasonography in the control of benign prostatic hyperplasia La Radiologia Medica 95(3): 182-187
Abdul-Muhsin, H.M.; Jakob, N.J.; McLemore, R.M.; McAdams, S.B.; Humphreys, M.R. 2016: Infectious complications associated with the use of temporary prostatic urethral stents in patients with benign prostatic hyperplasia Canadian Journal of Urology 23(5): 8465-8470
Pretlow, T.G.; Whitehurst, G.B.; Pretlow, T.P.; Hunt, R.S.; Jacobs, J.M.; McKenzie, D.R.; McDaniel, H.G.; Hall, L.M.; Bradley, E.L. 1982: Decrease in creatine kinase in human prostatic carcinoma compared to benign prostatic hyperplasia Cancer Research 42(11): 4842-4848
Granados Loarca, E.A. 1999: Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume Archivos Espanoles de Urologia 52(3): 201-208
Goldenberg, D.M.; DeLand, F.H. 1984: Clinical studies of prostatic cancer imaging with radiolabeled antibodies against prostatic acid phosphatase Urologic Clinics of North America 11(2): 277-281
Kazama, T.; Mizuno, I.; Takamine, T.; Umeda, K.; Terada, T.; Ishikawa, S.; Fuse, H.; Katayama, T. 1990: Evaluation of anti-androgen therapy for benign prostatic hypertrophy by using transrectal prostatic ultrasonography Hinyokika Kiyo. Acta Urologica Japonica 36(12): 1423-1427
Teni, T.R.; Bandivdekar, A.H.; Sheth, A.R.; Sheth, N.A. 1989: Prostatic inhibin-like peptide quantified in urine of prostatic cancer patients by enzyme-linked immunosorbent assay Clinical Chemistry 35(7): 1376-1379